K. T. Park

K. T. Park

Auto-generated profile, based on publicly available information

K. T. Park

Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, California, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HYH. Yu
H. Yu
DMD. MacIsaac
D. MacIsaac
JWJ. J. Wong
J. J. Wong
ZSZ. M. Sellers
Z. M. Sellers
AWA. A. Wren
A. A. Wren
KPK. T. Park
K. T. Park

1 June 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
AHAnke Heida
Anke Heida
KPK. T. Park
K. T. Park
PRPatrick F. van Rheenen
Patrick F. van Rheenen
Background. In asymptomatic patients with inflammatory bowel disease (IBD), “monitoring” involves repeated testing aimed at early recognition of disease exacer

1 July 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
KPK. T. Park
K. T. Park
DBDorsey Bass
Dorsey Bass

1 February 2014 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
ZYZhuo Yang
Zhuo Yang
NCNick Clark
Nick Clark
KPK.T. Park
K.T. Park

1 May 2016 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
LYLauren Yokomizo
Lauren Yokomizo
BLBerkeley Limketkai
Berkeley Limketkai
KPK T Park
K T Park
Background There are no head-to-head randomised controlled trials (RCTs) comparing the effectiveness of biologics in ulcerative colitis (UC). We aimed to assess the cost-effectiveness of adalimumab, infliximab and vedolizumab as first-line agents to induce clinical remission and mucosal healing (MH) in UC. Methods We constructed a decision tree based on a payer's perspective in the USA to estimate the first year costs of adalimumab, infliximab or vedolizumab to achieve clinical remission and MH in patients with moderate-to-severe UC. Transition probabilities were derived from ACT, ULTRA and GEMINI RCT data. Costs were derived from Medicare reimbursement rates and wholesale drug prices. Results Assuming a biological-naïve cohort, infliximab 5 mg/kg every 8 weeks was more cost-effective ($99 171 per MH achieved) than adalimumab 40 mg every other week ($316 378 per MH achieved) and vedolizumab every 8 weeks ($301 969 per MH achieved) at 1 year. Non-drug administration cost of infliximab exceeding $1974 per infusion would make adalimumab more cost-effective. First-line UC therapy with vedolizumab would be cost-effective if the drug acquisition price was <$2537 for each 300 mg administration during the 1-year time horizon. Conclusions If non-drug costs of infliximab administration are not excessive (<$2000), infliximab is the most cost-effective first-line biologic for moderate-to-severe UC. Exceeding this threshold infusion-related cost would make adalimumab the more cost-effective therapy. Considering its drug costs in the USA, vedolizumab appears to be appropriately used as a second-line biologic after antitumour necrosis factor failure.

1 July 2014 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
KPK. T. Park
K. T. Park
ASAaron Sin
Aaron Sin
MWMay Wu
May Wu
DBDorsey Bass
Dorsey Bass
JBJay Bhattacharya
Jay Bhattacharya
Background. Utilization trends and health effects of infliximab and adalimumab in inflammatory bowel disease (IBD) are incompletely understood. We aimed to des